352 related articles for article (PubMed ID: 20092879)
1. Overactive bladder is not only overactive but also hypersensitive.
Lee SR; Kim HJ; Kim A; Kim JH
Urology; 2010 May; 75(5):1053-9. PubMed ID: 20092879
[TBL] [Abstract][Full Text] [Related]
2. Reproducibility of urodynamic filling sensation at weekly interval in healthy volunteers and in women with detrusor overactivity.
Van Meel TD; Wyndaele JJ
Neurourol Urodyn; 2011 Nov; 30(8):1586-90. PubMed ID: 21538500
[TBL] [Abstract][Full Text] [Related]
3. Comparisons of urodynamic characteristics between female patients with overactive bladder and overactive bladder plus stress urinary incontinence.
Lin LY; Yeh NH; Lin CY; Sheu BC; Lin HH
Urology; 2004 Nov; 64(5):945-9. PubMed ID: 15533483
[TBL] [Abstract][Full Text] [Related]
4. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity.
Nitti VW; Rovner ES; Bavendam T
BJU Int; 2010 May; 105(9):1268-75. PubMed ID: 19889062
[TBL] [Abstract][Full Text] [Related]
5. Analysis of bladder diary with urinary perception to assess overactive bladder symptoms in community-dwelling women.
Honjo H; Kawauchi A; Ukimura O; Nakao M; Kitakoji H; Miki T
Neurourol Urodyn; 2009; 28(8):982-5. PubMed ID: 19267392
[TBL] [Abstract][Full Text] [Related]
6. Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention.
Liu HT; Kuo HC
Neurourol Urodyn; 2009; 28(1):78-81. PubMed ID: 19089891
[TBL] [Abstract][Full Text] [Related]
7. Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence.
Kuo HC; Liu HT; Chancellor MB
Neurourol Urodyn; 2010 Mar; 29(3):482-7. PubMed ID: 19367641
[TBL] [Abstract][Full Text] [Related]
8. Urgency severity scale could predict urodynamic detrusor overactivity in patients with overactive bladder syndrome.
Chung SD; Liao CH; Chen YC; Kuo HC
Neurourol Urodyn; 2011 Sep; 30(7):1300-4. PubMed ID: 21560153
[TBL] [Abstract][Full Text] [Related]
9. How sudden is a compelling desire to void? An observational cystometric study on the suddenness of this sensation.
De Wachter S; Wyndaele JJ
BJU Int; 2008 Apr; 101(8):1000-3. PubMed ID: 18218058
[TBL] [Abstract][Full Text] [Related]
10. Urodynamic findings in female diabetic patients with and without overactive bladder symptoms.
Ho CH; Tai HC; Yu HJ
Neurourol Urodyn; 2010 Mar; 29(3):424-7. PubMed ID: 19283863
[TBL] [Abstract][Full Text] [Related]
11. Understanding the elements of overactive bladder: questions raised by the EPIC study.
Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K;
BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602
[TBL] [Abstract][Full Text] [Related]
12. Bladder diary patterns in detrusor overactivity and urodynamic stress incontinence.
Parsons M; Amundsen CL; Cardozo L; Vella M; Webster GD; Coats AC;
Neurourol Urodyn; 2007; 26(6):800-6. PubMed ID: 17335054
[TBL] [Abstract][Full Text] [Related]
13. Defining overactive bladder as hypersensitivity.
Yamaguchi O; Honda K; Nomiya M; Shishido K; Kakizaki H; Tanaka H; Yamanishi T; Homma Y; Takeda M; Araki I; Obara K; Nishizawa O; Igawa Y; Goto M; Yokoyama O; Seki N; Takei M; Yoshida M
Neurourol Urodyn; 2007 Oct; 26(6 Suppl):904-7. PubMed ID: 17663416
[TBL] [Abstract][Full Text] [Related]
14. Electromotive drug-administration: a pilot study for minimal-invasive treatment of therapy-resistant idiopathic detrusor overactivity.
Bach P; Wormland RT; Möhring C; Goepel M
Neurourol Urodyn; 2009; 28(3):209-13. PubMed ID: 19205067
[TBL] [Abstract][Full Text] [Related]
15. Correlation between cystometric volumes, ATP release, and pH in women with overactive bladder versus controls.
Cheng Y; Mansfield KJ; Allen W; Millard RJ; Burcher E; Moore KH
Neurourol Urodyn; 2013 Sep; 32(7):969-73. PubMed ID: 23129360
[TBL] [Abstract][Full Text] [Related]
16. Bladder sensations during filling cystometry are different according to urodynamic diagnosis.
Digesu GA; Basra R; Khullar V; Hendricken C; Camarata M; Kelleher C
Neurourol Urodyn; 2009; 28(3):191-6. PubMed ID: 18973145
[TBL] [Abstract][Full Text] [Related]
17. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
18. Desmopressin, as a "designer-drug," in the treatment of overactive bladder syndrome.
Hashim H; Malmberg L; Graugaard-Jensen C; Abrams P
Neurourol Urodyn; 2009; 28(1):40-6. PubMed ID: 18726947
[TBL] [Abstract][Full Text] [Related]
19. Does adenosine triphosphate released into voided urodynamic fluid contribute to urgency signaling in women with bladder dysfunction?
Cheng Y; Mansfield KJ; Allen W; Walsh CA; Burcher E; Moore KH
J Urol; 2010 Mar; 183(3):1082-6. PubMed ID: 20092837
[TBL] [Abstract][Full Text] [Related]
20. The effect of rectal distension on bladder function in patients with overactive bladder.
Akl MN; Jacob K; Klauschie J; Crowell MD; Kho RM; Cornella JL
Neurourol Urodyn; 2012 Apr; 31(4):541-3. PubMed ID: 22275153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
